Clinical

Obecabtagene autoleucel showed over 70% response rates in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), demonstrating efficacy across all age groups in recent trials.

Many FDA accelerated approvals continue to rely heavily on surrogate endpoints, raising ongoing uncertainty about the true clinical benefits of these therapies.

Long-term results from the phase 2 OVARIO trial (NCT03326193) highlight the effectiveness of niraparib plus bevacizumab as maintenance therapy in patients with advanced ovarian cancer.

Glucagon-like peptide-1 (GLP-1) receptor agonists significantly enhance overall survival in patients with ovarian cancer, offering a promising adjunct to traditional treatments.

Significant gaps in arthritis subtype awareness among US adults underscore the need for improved health literacy and more targeted public health efforts.

Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.

Panelists discuss how cost-effectiveness analyses of newer therapies like sotatercept show substantial benefits in reducing clinical worsening events and potentially decreasing downstream costs through reduced hospitalizations and transplantations, supporting value-based payment models.

US ovarian cancer mortality rates declined from 1999 to 2020, but significant disparities remain across age, race, and geographic regions, highlighting the need for targeted public health efforts.

Patients with bronchiectasis face heightened risks of severe exacerbation and mortality after COVID-19 recovery, especially following severe cases.

Encounter-level factors played a key role in limiting outpatient COVID-19 treatment for Black and Latino patients.

Although use of corticosteroid premedication prior to infliximab infusions is declining, it remains unnecessarily high despite limited benefit and the risk of serious adverse events from corticosteroids.

An expert discusses how multidisciplinary collaboration can be enhanced through shared knowledge of available drugs and biomarkers among oncologists and pathologists, standardized interpretation methods across different cancer types, and clear communication about trial-specific algorithms to optimize treatment plans and ensure proper biomarker assessment.

Panelists discuss how emerging therapies like CAR T cells and bispecific antibodies may transform frontline treatment by potentially replacing transplant or changing induction regimens, while considering the cost implications and need for sustainable care models.

An expert discusses how the biggest barriers to incorporating antibody-drug conjugates (ADCs) include lacking biomarker knowledge and how payer restrictions can be overcome through early biomarker testing, proper documentation of target expression levels, and following FDA or National Comprehensive Cancer Network (NCCN) guidelines to ensure patient access to appropriate therapies.

Panelists discuss how early relapse in standard-risk patients represents a failure of current risk assessment methods and may require advanced sequencing technologies to identify hidden high-risk features that traditional fluorescence in situ hybridization testing misses.

Following 16 weeks of rezpegaldesleukin treatment in the REZOLVE-AD study, primary and key secondary end points have been met.

Advancements in B-cell therapies, including anti-CD20 and anti-CD19 monoclonal antibodies, enhance treatment efficacy and safety for multiple sclerosis and autoimmune diseases.

Panelists discuss how patient perspectives on new therapies center around clinically meaningful outcomes and survival while balancing individual risk tolerance, with some patients willing to accept higher risks for potentially transformative treatments in devastating diseases.

Panelists discuss how exciting ongoing research efforts are expanding similar gene therapy technologies to other muscular dystrophies like FSHD and myotonic dystrophy, using strategies to knock down rather than restore gene expression for these autosomal dominant conditions.

A panelist discusses how the ASCERTAIN-V study demonstrated that an all-oral combination of decitabine-cedazuridine plus venetoclax achieved a 47% complete response rate and 15.5-month median overall survival in older, unfit AML patients, representing a potential new standard of care that eliminates the need for intravenous infusions and significantly reduces clinic time burden while serving as a backbone for future oral combination therapies.

Collaborations between academic and community cancer centers enhance access to care, with success in acute myeloid leukemia and precision oncology.

The indirect comparative analysis is the first of its kind to assess the relative efficacy of approved covalent Bruton tyrosine kinase inhibitors (cBTKis) in the absence of head-to-head trials.

Carrie Kitko, MD, explains that axatilimab maintains strong response rates in patients with chronic graft-versus-host disease (GVHD) regardless of previous treatment lines and emphasizes the need to explore combination therapies.

Panelists discuss how unconscious bias and weight stigma create barriers to care, requiring providers to acknowledge their own biases, create welcoming clinical environments with appropriate accommodations, and approach patients with compassion rather than judgment about willpower.

Panelists discuss how effective provider-patient communication about weight requires opening conversations with empathy and collaboration, using phrases like "I'm concerned about your weight" and avoiding stigmatizing language while understanding patient motivations and readiness for change.

A panelist discusses how personalized ITP care requires open conversations about testing costs, insurance coverage, and treatment accessibility, with clinicians helping patients navigate financial barriers through pharmaceutical assistance programs and clinical trials.

Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being reviewed by the FDA.

Panelists discuss how patient financial burden varies significantly by insurance type and often leads to treatment interruptions, while prior authorization barriers create administrative challenges that could be improved through better collaboration between medical and payer communities.

Panelists discuss how healthcare resource utilization is primarily driven by hospitalizations, medication costs, and outpatient monitoring, with early diagnosis and treatment potentially reducing long-term costs by preventing disease progression and avoiding expensive advanced therapies.